In:
Circulation, Ovid Technologies (Wolters Kluwer Health), Vol. 144, No. Suppl_1 ( 2021-11-16)
Abstract:
Introduction: Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited heart disease. The presence of a sarcomere mutation is a powerful predictor of adverse outcomes. Two-thirds of the patients are obstructive HCM (OHCM). Atrial fibrillation (AF), a common complication, is associated with poor long-term prognosis in OHCM patients. However, the effect of sarcomere mutation on the clinical phenotype or prognosis in OHCM patients with AF is unknown. Methods and Results: We retrospectively collected 41 OHCM patients with AF who underwent septal myectomy in Fuwai hospital which were separated into 2 groups, sarcomere mutation (+) group and sarcomere mutation (-) group (n=25 and 16). Statistical analysis was performed by Mann-Whitney U test, Chi-square test, Kaplan-Meier survival analysis, and log-rank test with SPSS 23.0 and GraphPad 8.0. Patients in sarcomere mutation (+) group were younger (42.0±14.5 vs. 57.6±11.7 years, p=0.001). There was no significant difference between sarcomere mutation (+) and sarcomere mutation (-) group on other baseline variables and prognosis (log-rank p=0.077). Conclusions: In conclusion, we did not find that the presence of a sarcomere mutation worsen the prognosis in OHCM patients with AF. Multi-center prospective studies with large samples are needed to further confirm our results.
Type of Medium:
Online Resource
ISSN:
0009-7322
,
1524-4539
DOI:
10.1161/circ.144.suppl_1.12240
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2021
detail.hit.zdb_id:
1466401-X
